ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1927

A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil

Ami A. Shah1, Elena Schiopu2, Soumya Chatterjee3, Mary Ellen Csuka4, Tracy Frech5, Avram Goldberg6, Robert F. Spiera7, Stanford L. Peng8 and Virginia D. Steen9, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, University of Michigan, Ann Arbor, MI, 3Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, 4Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 5Div of Rheumatology, University of Utah, Salt Lake City, UT, 6Div of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Benaroya Research Institute/Virginia Mason, Seattle, WA, 9Department of Rheumatology, Georgetown University Medical Center, Washington, DC

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Raynaud's phenomenon, systemic sclerosis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for oral delivery, improves cutaneous perfusion and temperature in SSc. A large randomized, double-blind, placebo-controlled clinical trial of treprostinil was conducted in SSc patients with DU. While this trial did not meet the desired endpoint (change in net ulcer burden at 20 wks), there was a significant improvement in several secondary endpoints that measured Raynaud’s severity. Subjects enrolled into an open label extension study (DISTOL-EXT) after the clinical trial; after termination of DISTOL-EXT, all participants were withdrawn from oral treprostinil. We investigated whether active, indeterminate, and total DU burden increased in DISTOL-EXT participants after they discontinued treprostinil.


Methods

In this multi-center, retrospective study, medical records for the year after discontinuation of treprostinil were reviewed. Data from these routine clinical visits were abstracted into a template designed a priori to capture information on the number of active and indeterminate DU at the end of the extension study and at subsequent visits. Participants who did not have a subsequent visit with documentation of DU status were excluded. We examined the number of new DU that developed from the end of the extension study (baseline) through the first year after discontinuation of treprostinil. The number of active, indeterminate and total DU 3-6 months (time A) and >6-12 months (time B) after discontinuation of treprostinil were compared to baseline by the paired t-test.


Results

Fifty-one subjects from 9 SSc Centers were included for analysis. At the conclusion of the treprostinil extension study, the mean number of active, indeterminate and total DU was 0.25 (SD 0.63), 0.22 (SD 0.54) and 0.47 (SD 0.78), respectively. The number of active DU increased from baseline to time A (mean 1.62, p=0.004, N=23) and time B (mean 1.03, p=0.076, N=30). The number of indeterminate DU increased from baseline to time B (mean 0.42, p=0.03, N=30) but not time A. The total DU burden increased significantly from baseline to time A (mean 2.1, p=0.002, N=23) and time B (mean 1.45, p=0.01, N=30) as shown in the Figure. The majority of patients required intensive vasodilator therapy and pain medication: calcium channel blockers (60.8%), PDE 5 inhibitors (21.6%), any pain medication (58.8%), opioids (33.3%). Three patients were hospitalized for complications from digital ulcers, and 4 patients required surgical intervention. Five patients were subsequently diagnosed with pulmonary hypertension.

Conclusion

Total DU burden increased significantly after discontinuation of oral treprostinil diolamine. These data provide supportive evidence of a beneficial effect of oral treprostinil diolamine for the vascular complications of SSc.


Disclosure:

A. A. Shah,

United Therapeutics,

2;

E. Schiopu,

United Therapeutics, Actelion, MedImmune, Celgene,

2,

United Therapeutics,

8;

S. Chatterjee,

United Therapeutics,

2;

M. E. Csuka,

United Therapeutics,

2;

T. Frech,

United Therapeutics,

2;

A. Goldberg,

United Therapeutics,

2;

R. F. Spiera,

United Therapeutics,

2;

S. L. Peng,

United Therapeutics,

2;

V. D. Steen,

Actelion Pharmaceuticals US,

8,

United Therapeutics,

5,

Gilead Science,

8,

Roche Pharmaceuticals,

2,

Sanofi-Aventis Pharmaceutical,

2,

CSL Berhing,

2,

Intermune,

2,

Bayer,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-retrospective-look-at-the-recurrence-of-digital-ulcers-in-patients-with-scleroderma-after-discontinuation-of-oral-treprostinil/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology